The Past Three Years for Seres Therapeutics (NASDAQ:MCRB) Investors Has Not Been Profitable

Yahoo Finance2024/12/26 21:04

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Seres Therapeutics2024/12/16 13:00

Seres Therapeutics' SER-155 Receives FDA Breakthrough Therapy Designation for Bloodstream Infection Reduction

Benzinga2024/12/09 20:03

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)

Seres Therapeutics2024/12/09 13:00

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Seres Therapeutics2024/11/22 13:00

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Simply Wall St2024/11/15 20:08